{"name":"Daiichi Sankyo Co., Ltd.","slug":"daiichi-sankyo","ticker":"DSNKY","exchange":"OTC","domain":"daiichisankyo.com","description":"Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatm","hq":"Tokyo, Japan","founded":2005,"employees":"~19,765","ceo":"Sunao Manabe","sector":"Big Pharma","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":16.31,"stockChange":-0.88,"stockChangePercent":-5.12,"marketCap":"$188M","metrics":{"revenue":13421618175.749863,"revenueGrowth":13.7,"grossMargin":68.5,"rdSpend":0,"netIncome":1642890065.9358106,"cash":2843622089.1409287,"dividendYield":2.65,"peRatio":18.3,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Enhertu","genericName":"trastuzumab-deruxtecan","slug":"trastuzumab-deruxtecan","revenue":2900000000,"yoyGrowth":0,"percentOfTotal":58},{"name":"Savaysa","genericName":"edoxaban","slug":"edoxaban","revenue":1800000000,"yoyGrowth":0,"percentOfTotal":36},{"name":"Tarlige","genericName":"MIROGABALIN","slug":"mirogabalin","revenue":300000000,"yoyGrowth":0,"percentOfTotal":6}],"timeline":[{"date":"2015-01-01","label":"Savaysa first approved","drug":"Savaysa","drugSlug":"edoxaban","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Enhertu first approved","drug":"Enhertu","drugSlug":"trastuzumab-deruxtecan","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Vanflyta first approved","drug":"Vanflyta","drugSlug":"quizartinib","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Datroway first approved","drug":"Datroway","drugSlug":"deruxtecan","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-07-31","label":"Datroway PHASE3 readout","drug":"Datroway","drugSlug":"deruxtecan","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-15","label":"Datroway PHASE3 readout","drug":"Datroway","drugSlug":"deruxtecan","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Edoxaban patent cliff ($1.4B at risk)","drug":"Edoxaban","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Tivantinib patent cliff ($0.2B at risk)","drug":"Tivantinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":2900000000,"percentOfTotal":58,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Enhertu","genericName":"trastuzumab-deruxtecan","slug":"trastuzumab-deruxtecan","indication":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","status":"marketed","revenue":2900000000},{"name":"Ezharmia","genericName":"VALEMETOSTAT","slug":"valemetostat","indication":"Relapsed or refractory T-cell leukemia-lymphoma","status":"marketed"},{"name":"Datroway","genericName":"DERUXTECAN","slug":"deruxtecan","indication":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","status":"marketed"},{"name":"TURALIO™","genericName":"TURALIO™","slug":"turalio","indication":"Tenosynovial giant cell tumor","status":"marketed"},{"name":"Vanflyta","genericName":"QUIZARTINIB","slug":"quizartinib","indication":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","status":"marketed"}]},{"name":"Other","slug":"other","revenue":1800000000,"percentOfTotal":36,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Savaysa","genericName":"edoxaban","slug":"edoxaban","indication":"Stroke risk reduction in NVAF","status":"marketed","revenue":1800000000},{"name":"Hydroclorothiazide","genericName":"Hydroclorothiazide","slug":"hydroclorothiazide","indication":"Other","status":"marketed"},{"name":"14C-Quizartinib solution for infusion","genericName":"14C-Quizartinib solution for infusion","slug":"14c-quizartinib-solution-for-infusion","indication":"Other","status":"phase_1"},{"name":"Buproprion","genericName":"Buproprion","slug":"buproprion","indication":"Other","status":"phase_1"},{"name":"DS-3201b","genericName":"DS-3201b","slug":"ds-3201b","indication":"Other","status":"phase_1"},{"name":"Inavir","genericName":"laninamivir octanoate hydrate","slug":"laninamivir-octanoate-hydrate","indication":"Influenza","status":"marketed"},{"name":"Low-dose colesevelam","genericName":"Low-dose colesevelam","slug":"low-dose-colesevelam","indication":"Other","status":"marketed"},{"name":"Mevalotin","genericName":"Mevalotin","slug":"mevalotin","indication":"Other","status":"phase_2"},{"name":"colesevelam HCl tablets and fenofibrate tablets","genericName":"colesevelam HCl tablets and fenofibrate tablets","slug":"colesevelam-hcl-tablets-and-fenofibrate-tablets","indication":"Other","status":"marketed"},{"name":"hydrochlorothiazide tablets","genericName":"hydrochlorothiazide tablets","slug":"hydrochlorothiazide-tablets","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":300000000,"percentOfTotal":6,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Tarlige","genericName":"MIROGABALIN","slug":"mirogabalin","indication":"Diabetic peripheral neuropathy","status":"marketed","revenue":300000000}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Gracevit","genericName":"SITAFLOXACIN","slug":"sitafloxacin","indication":"Respiratory tract infection","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Minnebro","genericName":"esaxerenone","slug":"esaxerenone","indication":"Diabetic nephropathy","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Welchol","genericName":"Welchol","slug":"welchol","indication":"Hypercholesterolemia","status":"marketed"}]}],"pipeline":[{"name":"Enhertu","genericName":"trastuzumab-deruxtecan","slug":"trastuzumab-deruxtecan","phase":"marketed","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells.","indications":["Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","Metastatic human epidermal growth factor 2 positive carcinoma of breast"],"catalyst":""},{"name":"Savaysa","genericName":"edoxaban","slug":"edoxaban","phase":"marketed","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting.","indications":["Stroke risk reduction in NVAF","DVT and PE treatment"],"catalyst":""},{"name":"Tarlige","genericName":"MIROGABALIN","slug":"mirogabalin","phase":"marketed","mechanism":"Voltage-dependent calcium channel subunit alpha-2/delta-1","indications":["Diabetic peripheral neuropathy","Peripheral neuropathic pain","Postherpetic neuralgia"],"catalyst":""},{"name":"Hydroclorothiazide","genericName":"Hydroclorothiazide","slug":"hydroclorothiazide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ezharmia","genericName":"VALEMETOSTAT","slug":"valemetostat","phase":"marketed","mechanism":"Histone-lysine N-methyltransferase EZH2","indications":["Relapsed or refractory T-cell leukemia-lymphoma"],"catalyst":""},{"name":"14C-Quizartinib solution for infusion","genericName":"14C-Quizartinib solution for infusion","slug":"14c-quizartinib-solution-for-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buproprion","genericName":"Buproprion","slug":"buproprion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DS-3201b","genericName":"DS-3201b","slug":"ds-3201b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Datroway","genericName":"DERUXTECAN","slug":"deruxtecan","phase":"marketed","mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells.","indications":["Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer"],"catalyst":""},{"name":"Gracevit","genericName":"SITAFLOXACIN","slug":"sitafloxacin","phase":"marketed","mechanism":"Small molecule","indications":["Respiratory tract infection","Urinary tract infectious disease"],"catalyst":""},{"name":"Inavir","genericName":"laninamivir octanoate hydrate","slug":"laninamivir-octanoate-hydrate","phase":"marketed","mechanism":"","indications":["Influenza"],"catalyst":""},{"name":"Low-dose colesevelam","genericName":"Low-dose colesevelam","slug":"low-dose-colesevelam","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mevalotin","genericName":"Mevalotin","slug":"mevalotin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Minnebro","genericName":"esaxerenone","slug":"esaxerenone","phase":"marketed","mechanism":"Mineralocorticoid receptor","indications":["Diabetic nephropathy","Hypertension"],"catalyst":""},{"name":"TURALIO™","genericName":"TURALIO™","slug":"turalio","phase":"marketed","mechanism":"Turalio works by inhibiting a specific biological pathway.","indications":["Tenosynovial giant cell tumor"],"catalyst":""},{"name":"Vanflyta","genericName":"QUIZARTINIB","slug":"quizartinib","phase":"marketed","mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells.","indications":["Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","Acute myeloid leukemia, disease"],"catalyst":""},{"name":"Welchol","genericName":"Welchol","slug":"welchol","phase":"marketed","mechanism":"Small molecule","indications":["Hypercholesterolemia","Type 2 Diabetes Mellitus Treatment Adjunct"],"catalyst":""},{"name":"colesevelam HCl tablets and fenofibrate tablets","genericName":"colesevelam HCl tablets and fenofibrate tablets","slug":"colesevelam-hcl-tablets-and-fenofibrate-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"hydrochlorothiazide tablets","genericName":"hydrochlorothiazide tablets","slug":"hydrochlorothiazide-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-01","type":"regulatory","headline":"FDA Approves Daiichi Sankyo's Trastuzumab Deruxtecan for HER2-Positive Breast Cancer","summary":"The US FDA has approved Trastuzumab deruxtecan (DS-8201a) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.","drugName":"Trastuzumab deruxtecan (DS-8201a)","sentiment":"positive"},{"date":"2022-08-04","type":"earnings","headline":"Daiichi Sankyo Reports Strong Second-Quarter Earnings","summary":"Daiichi Sankyo Co., Ltd. reported strong second-quarter earnings, driven by the success of its marketed products and pipeline progress.","drugName":"","sentiment":"positive"},{"date":"2022-06-01","type":"deal","headline":"Daiichi Sankyo and AstraZeneca Announce Collaboration on Oncology Pipeline","summary":"Daiichi Sankyo Co., Ltd. and AstraZeneca have announced a collaboration to co-develop and co-commercialize several oncology pipeline products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxObko1Q0o2UFRQaTlRVDNpR3JvNGdsRUVWNEZ0cG5XMnRuNXVsMjBoQzdrdzdyQzBuaXdCSDV3Y2hWUndqYS03bDVZcE52bnpLTEdzUlUyaXZVQzZ5YWNwRDV4YXNocXdlMFFCZ2JSbmsyLU1LWXRDWVZTVXh0OUlHTlFaT0Nqd2pNX1pubUhMWlEtLVBxQUZYU2lzeE9Ic2pFV01FQUtLbTkyQQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Seeking Alpha","summary":"Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued (OTCMKTS:DSNKY) - Seeking Alpha","headline":"Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued (OTCMKTS:DSNKY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQcW5NcHNUNjJjWldSY1lrZVd5U09KYlJJWVFLVkJ0SzF4WmUtQ3pveUU1eHdBdXF3bi1HQ1VYZVE3ZGR5ZDVYdldCQ0NtSGJiRWdXRzQtWW55ZEl6WlV4UDlWN1laaUZYOWpVZEk2QVZqM1k3TUZ3cm1aQlFoUEhlVktacVhiZXNaNTBV?oc=5","date":"2026-02-03","type":"regulatory","source":"Seeking Alpha","summary":"AstraZeneca provides mixed regulatory updates (AZN:NYSE) - Seeking Alpha","headline":"AstraZeneca provides mixed regulatory updates (AZN:NYSE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNY1dLelVPR05IckFnMFAyTUV3MzIzck5ESGRYY1cxVktPTU5LZ08yZE1ZdzdGcGZ4dW5oa1NiVV9vZGFfUlY0clNFZE5SXy1KdWZQdmFYSjF1U2FXYTZVQ0Zkc1JweUdfOTAwcGtZdFdVbE1MM2c1WG1tajNfSFJ5M2tqS3pzanl4N1dnVWFhZnplRVFieC1hUUJaZDVjV2NfeE5meE51SGpDVkJJSnBmY09QdjNyQUplNVlXRHNNbFpveFlsVzE1YUxHYw?oc=5","date":"2026-01-21","type":"earnings","source":"Investing.com","summary":"Daiichi Sankyo opens Toronto headquarters to fuel Canadian oncology growth - Investing.com","headline":"Daiichi Sankyo opens Toronto headquarters to fuel Canadian oncology growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5HX281dWQyeWJKWGdwZ1l2VnA1djViVy0zTWhmbzdPWnpkSjdUOTk5dlBHVV8xeTY2SnlibkI5bkotWGNEM210aWRYSVJhYUJvcmNmMTRfQWI1YVBwb1JNWXlMYUx6cWEtWkRBVmgwVHFBWnNzWmtpVmZBaS0?oc=5","date":"2025-12-17","type":"pipeline","source":"Yahoo Finance","summary":"CPRX vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance","headline":"CPRX vs. DSNKY: Which Stock Is the Better Value Option?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPck45QXM4dEswQkhjLXY2WTc1YWZmVTJ4dkNPcnd6N2I1ZTZUTDNQcWRHQTJ3am0xY3JTOXJwQ3Mxb3F3d2JCZTRLYU1FVV9ud2pIOUwyQ2pyZTQ0SkVKMWl0Qmc2aUFkQW5WWndlemg2b2VQbHpqWkgxeGc2bk4zbDZGb0R3dHo0bTlYVWw3RmdkdE82N2I0U2lwMkZXdGc?oc=5","date":"2025-04-11","type":"pipeline","source":"Seeking Alpha","summary":"Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha","headline":"Daiichi Sankyo: Good Diversification Tool For U.S. Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOSmhFRm82c2FrUEN1ZHZSaE8xbm50dEVINTVoTDBfSGcxY3ZScS1MNXpZcjRza3lnYzkxdzZhbGNjYmxqWHdha2x6TjZGSDNGdm9reGF4dmw1NVJYSGlLY3E5YTZXQUN0c1dLMFh4Vlo4dEJWaUlna2l1RXVyQkNBY2MzQjJNR1FwOUFiT1NfdHFteW42ZHFCNHRENFpPM2htNk9oSmQzRVNLUndmYllyMjRPNEpLMjBidTdVRmxLWQ?oc=5","date":"2025-01-10","type":"trial","source":"Seeking Alpha","summary":"High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF) - Seeking Alpha","headline":"High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF)","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9IZ1NEc011VjV6VFhTUXhYMHBRUEhjUE9MTUxqbUVuZjJDU1JtS3BEU2VYLUljejZQQTRQUWRaWndsVXVvOVlaZTBnRHZ4MjNOaVR6N1hycWNNN3Jf?oc=5","date":"2018-02-21","type":"pipeline","source":"MarketBeat","summary":"Daiichi Sankyo (DSNKY) Stock Price, News & Analysis - MarketBeat","headline":"Daiichi Sankyo (DSNKY) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFA2Z05hQ1B1MkVNaG93QzN4SmFQQ0hmUFgtSEs5WE5QTDY5Wm9oY3oyaG5SVy0yalhhQVNZYlhKaURiVEhJYVVTeko0MUxmd1I2b3Y4?oc=5","date":"2017-05-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Daiichi Sankyo Company, Limited (DSKYF) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Daiichi Sankyo Company, Limited (DSKYF) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1tMTN1RlR6RlZPNUV3STZfZjZfTE1WMDBjZjdZY29tZHNPRm40cWNXRWprQk9PVGhsVmQxNXlyM3ZpNzA3djZ6c0dwcGVEYXJLU2hN?oc=5","date":"2017-05-22","type":"pipeline","source":"Yahoo Finance UK","summary":"Chugai Pharmaceutical Co., Ltd. (CHGCY) stock price, news, quote and history - Yahoo Finance UK","headline":"Chugai Pharmaceutical Co., Ltd. (CHGCY) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1kY0N3MDRKZExZYms4SDRlNlZUWTR0VUpXLUxyZHR3dkpYZmhWMUEwNGZud3RiSlBFcDFNVU1SemtsZFZuaUFCcEdDUHQwS3lxTFBB?oc=5","date":"2017-05-17","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Otsuka Holdings Co., Ltd. (OTSKY) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Otsuka Holdings Co., Ltd. (OTSKY) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Tivantinib","drugSlug":"tivantinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":200000000},{"drugName":"Edoxaban","drugSlug":"edoxaban","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":19,"phaseCounts":{"marketed":15,"phase_1":3,"phase_2":1},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":["Pfizer","Eli Lilly and Company","AstraZeneca"],"therapeuticFocus":["Oncology","Cardiovascular","Metabolic Diseases"],"financials":{"source":"yahoo_finance","revenue":11924668425.355202,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":11924668425.355202},{"period":"2024-03-31","value":10125666039.4296},{"period":"2023-03-31","value":8082373887.2726},{"period":"2022-03-31","value":6605673164.3564005}],"grossProfit":9296046816.2386,"grossProfitHistory":[{"period":"2025-03-31","value":9296046816.2386},{"period":"2024-03-31","value":7500053641.242201},{"period":"2023-03-31","value":5784209155.658401},{"period":"2022-03-31","value":4371517383.7047}],"rdSpend":2756114795.6905003,"rdSpendHistory":[{"period":"2025-03-31","value":2756114795.6905003},{"period":"2024-03-31","value":2308551566.8173003},{"period":"2023-03-31","value":2159361716.5690002},{"period":"2022-03-31","value":1645747572.1742}],"sgaSpend":4622552587.04,"operatingIncome":2098387264.0225,"operatingIncomeHistory":[{"period":"2025-03-31","value":2098387264.0225},{"period":"2024-03-31","value":1337638511.1313},{"period":"2023-03-31","value":762303933.3294001},{"period":"2022-03-31","value":461667324.6359}],"netIncome":1869731486.5052001,"netIncomeHistory":[{"period":"2025-03-31","value":1869731486.5052001},{"period":"2024-03-31","value":1268995628.2127001},{"period":"2023-03-31","value":690272527.1796},{"period":"2022-03-31","value":423388391.49240005}],"eps":155.87,"epsHistory":[{"period":"2025-03-31","value":155.87},{"period":"2024-03-31","value":104.62},{"period":"2023-03-31","value":56.91},{"period":"2022-03-31","value":34.91}],"cash":4044973744.7846003,"cashHistory":[{"period":"2025-03-31","value":4044973744.7846003},{"period":"2024-03-31","value":4091388926.806},{"period":"2023-03-31","value":2793767863.5357003},{"period":"2022-03-31","value":4188094598.2009}],"totalAssets":21849140897.9323,"totalLiabilities":11586113230.205101,"totalDebt":640607903.1044,"equity":10263027667.727201,"operatingCashflow":340382216.07140005,"operatingCashflowHistory":[{"period":"2025-03-31","value":340382216.07140005},{"period":"2024-03-31","value":3788432191.1986003},{"period":"2023-03-31","value":723942815.8538},{"period":"2022-03-31","value":880168909.3042}],"capex":-1187702680.0224001,"capexHistory":[{"period":"2025-03-31","value":-1187702680.0224001},{"period":"2024-03-31","value":-776268947.9147},{"period":"2023-03-31","value":-425879208.9422},{"period":"2022-03-31","value":-484773765.6994}],"freeCashflow":-847320463.9510001,"dividendsPaid":-722697407.1289,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":16.31,"previousClose":17.19,"fiftyTwoWeekHigh":28.21,"fiftyTwoWeekLow":15.56,"fiftyTwoWeekRange":"15.56 - 28.21","fiftyDayAverage":17.7,"twoHundredDayAverage":21.58,"beta":-0.17,"enterpriseValue":-746157673.9445039,"forwardPE":0,"priceToBook":2.77,"priceToSales":0.01,"enterpriseToRevenue":-0.06,"enterpriseToEbitda":-0.39,"pegRatio":4.62,"ebitda":1937963436.0299063,"ebitdaMargin":14.4,"freeCashflow":-1425415336.013834,"operatingCashflow":490924940.7945032,"totalDebt":1899602248.9631426,"debtToEquity":18.1,"currentRatio":2.42,"returnOnAssets":3.8,"returnOnEquity":15.8,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":25.5,"targetHighPrice":29,"targetLowPrice":22,"dividendRate":0.46,"payoutRatio":0.26,"fiveYearAvgDividendYield":1.17,"exDividendDate":1759190400,"insiderHeldPercent":0,"institutionHeldPercent":0,"sharesOutstanding":1819653230,"floatShares":1819234710,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.89,"epsForward":0,"revenuePerShare":1147.34,"bookValue":5.88,"officers":[{"age":71,"name":"Mr. Sunao  Manabe D.V.M., Ph.D.","title":"Executive Chairperson"},{"age":63,"name":"Mr. Hiroyuki  Okuzawa","title":"President, CEO & Representative Director"},{"age":null,"name":"Tomohiro  Kodama","title":"Senior Executive Officer, Head of Global Corporate Planning & Management, CFO"},{"age":null,"name":"Tetsuya  Ohira","title":"Corporate Officer, Head of Business Transformation & CTO"},{"age":null,"name":"Naoto  Tsukaguchi","title":"Senior Executive Officer, Head of Global Legal & IP, GC"},{"age":null,"name":"Matt  Allegrucci","title":"Head of Global Compliance & Risk Management and Chief Compliance Officer"},{"age":61,"name":"Mr. Takashi  Matsumoto","title":"Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director"},{"age":75,"name":"Mr. Joji  Nakayama","title":"Senior Adviser"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.daiichisankyo.com/media_investors/investor_relations/index.html","website":"https://www.daiichisankyo.com","phone":"81 3 6225 1111"}}